Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Human immunodeficiency virus type 1 reverse transcriptase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | 3-hydroxy-3-methylglutaryl-CoA reductase, putative | 0.2603 | 1 | 1 |
Trypanosoma cruzi | 3-hydroxy-3-methylglutaryl-CoA reductase | 0.2603 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1071 | 0.3957 | 0.3957 |
Toxoplasma gondii | 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein | 0.0564 | 0.1955 | 1 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0496 | 0.1684 | 0.1684 |
Brugia malayi | CHE-14 protein | 0.1071 | 0.3957 | 0.3957 |
Echinococcus granulosus | Protein patched homolog 1 | 0.1071 | 0.3957 | 0.3957 |
Trichomonas vaginalis | 3-hydroxy-3-methylglutaryl-coenzyme A reductase, putative | 0.1221 | 0.4547 | 1 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0564 | 0.1955 | 0.1955 |
Plasmodium vivax | 3',5'-cyclic nucleotide phosphodiesterase, putative | 0.0069 | 0 | 0.5 |
Giardia lamblia | CAMP-specific 3,5-cyclic phosphodiesterase 4B | 0.0564 | 0.1955 | 0.43 |
Trichomonas vaginalis | 3-hydroxy-3-methylglutaryl-coenzyme A reductase, putative | 0.1221 | 0.4547 | 1 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0564 | 0.1955 | 0.1955 |
Loa Loa (eye worm) | hypothetical protein | 0.2603 | 1 | 1 |
Plasmodium vivax | cyclic nucleotide phosphodiesterase, putative | 0.0069 | 0 | 0.5 |
Brugia malayi | Probable 3',5'-cyclic phosphodiesterase R153.1, putative | 0.0496 | 0.1684 | 0.1684 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0564 | 0.1955 | 0.1955 |
Echinococcus granulosus | Niemann Pick C1 protein | 0.1071 | 0.3957 | 0.3957 |
Trichomonas vaginalis | 3-hydroxy-3-methylglutaryl-coenzyme A reductase, putative | 0.1221 | 0.4547 | 1 |
Echinococcus granulosus | hydroxymethylglutaryl coenzyme A reductase | 0.2603 | 1 | 1 |
Giardia lamblia | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 0.1221 | 0.4547 | 1 |
Trypanosoma cruzi | 3-hydroxy-3-methylglutaryl-CoA reductase, putative | 0.2603 | 1 | 1 |
Loa Loa (eye worm) | abnormal chemotaxis protein 14 | 0.1071 | 0.3957 | 0.3957 |
Schistosoma mansoni | niemann-pick C1 (NPC1) | 0.1071 | 0.3957 | 0.3957 |
Loa Loa (eye worm) | hypothetical protein | 0.0564 | 0.1955 | 0.1955 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0564 | 0.1955 | 0.1955 |
Plasmodium falciparum | cGMP-specific phosphodiesterase | 0.0069 | 0 | 0.5 |
Leishmania major | 3-hydroxy-3-methylglutaryl-CoA reductase | 0.2603 | 1 | 1 |
Trypanosoma brucei | RNA helicase, putative | 0.01 | 0.0124 | 0.0124 |
Plasmodium vivax | 3',5'-cyclic nucleotide phosphodiesterase, putative | 0.0069 | 0 | 0.5 |
Schistosoma mansoni | hydroxymethylglutaryl-CoA reductase (NADPH) | 0.2603 | 1 | 1 |
Plasmodium falciparum | phosphodiesterase delta, putative | 0.0069 | 0 | 0.5 |
Plasmodium falciparum | 3',5'-cyclic nucleotide phosphodiesterase, putative | 0.0069 | 0 | 0.5 |
Echinococcus multilocularis | Niemann Pick C1 protein | 0.1071 | 0.3957 | 0.3957 |
Plasmodium falciparum | 3',5'-cyclic nucleotide phosphodiesterase, putative | 0.0069 | 0 | 0.5 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0496 | 0.1684 | 0.1684 |
Plasmodium falciparum | cGMP-specific phosphodiesterase | 0.0069 | 0 | 0.5 |
Echinococcus granulosus | sterol regulatory element binding protein | 0.1071 | 0.3957 | 0.3957 |
Schistosoma mansoni | patched 1 | 0.1071 | 0.3957 | 0.3957 |
Trichomonas vaginalis | conserved hypothetical protein | 0.1071 | 0.3957 | 0.8703 |
Plasmodium vivax | phosphodiesterase gamma, putative | 0.0069 | 0 | 0.5 |
Schistosoma mansoni | camp-specific 35-cyclic phosphodiesterase | 0.0564 | 0.1955 | 0.1955 |
Plasmodium falciparum | phosphodiesterase gamma, putative | 0.0069 | 0 | 0.5 |
Echinococcus multilocularis | protein dispatched 1 | 0.1071 | 0.3957 | 0.3957 |
Mycobacterium ulcerans | hydroxymethylglutaryl-coenzyme a (HMG-CoA) reductase | 0.2603 | 1 | 0.5 |
Echinococcus multilocularis | protein patched | 0.1071 | 0.3957 | 0.3957 |
Schistosoma mansoni | hypothetical protein | 0.01 | 0.0124 | 0.0124 |
Echinococcus multilocularis | hydroxymethylglutaryl coenzyme A reductase | 0.2603 | 1 | 1 |
Echinococcus multilocularis | sterol regulatory element binding protein | 0.1071 | 0.3957 | 0.3957 |
Loa Loa (eye worm) | cyclic AMP specific phosphodiesterase PDE4D5A | 0.0496 | 0.1684 | 0.1684 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (functional) | = 181 uM | Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. | ChEMBL. | 1732552 |
CC50 (functional) | = 181 uM | Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. | ChEMBL. | 1732552 |
EC50 (functional) | = 2.7 uM | Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. | ChEMBL. | 1732552 |
EC50 (binding) | = 2.7 uM | Inhibitory concentration against HIV-1 reverse transcriptase | ChEMBL. | 9435895 |
EC50 (binding) | = 2.7 uM | Inhibitory concentration against HIV-1 reverse transcriptase | ChEMBL. | 9435895 |
Log 1/C (functional) | = 5.57 | Tested for 50% protection of MT-4 cells from HIV infection | ChEMBL. | No reference |
Selectivity index (functional) | = 67 | Ratio of EC50/CC50 | ChEMBL. | 1732552 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.